SCHEMBL2394385

SCHEMBL2394385

CC12CCCc3cc(C(=O)Nc4ccc(C(=O)O)c(Cl)c4)cc(c31)CCC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPT2 P23786 6/20 0.44
CPT1A P50416 6/20 0.44
CPT1B Q92523 6/20 0.44
RARA P10276 2/20 0.43
RARB P10826 2/20 0.43
RARG P13631 2/20 0.43
NPC1 O15118 6/20 0.41
RAB9A P51151 6/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
CYP26A1 O43174 1/20 0.40
PGR P06401 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2393263 0.89 SMN1; SMN2 (0.43) CPT2CPT1ACPT1BRARARARB
SCHEMBL2392941 0.88 KMT2A (0.54) RARARARBRARGNPC1RAB9A
SCHEMBL2398306 0.87 RARA (0.58) CPT2CPT1ACPT1BRARARARB
SCHEMBL2398289 0.85 NPC1 (0.45) CPT2CPT1ACPT1BRARARARB
SCHEMBL2394957 0.83 MEN1 (0.54) RARARARBRARGNPC1RAB9A
SCHEMBL2395262 0.80 CPT2 (0.46) CPT2CPT1ACPT1BNPC1RAB9A
SCHEMBL2390930 0.79 SMN1; SMN2 (0.50) RARARARBRARGNPC1RAB9A
SCHEMBL2392613 0.79 CPT2 (0.45) CPT2CPT1ACPT1BNPC1RAB9A
SCHEMBL2394352 0.78 NPC1 (0.45) RARARARBRARGNPC1RAB9A
SCHEMBL2394316 0.78 RARA (0.46) CPT2CPT1ACPT1BRARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RXRA, RXRB, RXRG CPT2 343/4885CPT1A 249/4885CPT1B 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.